Malignant Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
As such, MGMT is gaining increasing traction in diagnosis, prognostication, and therapeutic decision-making for these highly malignant gliomas.
|
30444735 |
2019 |
Malignant Glioma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
MGMT promoter methylation is not correlated with integrin expression in malignant gliomas: clarifying recent clinical trial results.
|
29882028 |
2018 |
Malignant Glioma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
The study purpose was to investigate the non-invasive predictability of IDH mutation status, MGMT promoter methylation, and differentiation of low-grade versus high-grade glioma (LGG vs HGG) in newly diagnosed patients employing relaxation-compensated multipool chemical exchange saturation transfer (CEST) MRI at 7.0 Tesla.
|
29733378 |
2018 |
Malignant Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Logistic regression analysis showed that Leu84Phe of MGMT gene and pathological grade were independent risk factors for the increase of TMZ resistance in patients with malignant gliomas.
|
28409559 |
2017 |
Malignant Glioma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
MGMT promoter methylation determined by HRM in comparison to MSP and pyrosequencing for predicting high-grade glioma response.
|
27158275 |
2016 |
Malignant Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our study identified clinicopathological factors related to postoperative seizure in HGGs and found two predictive biomarkers of postoperative seizure: MGMT and EGFR.
|
26808114 |
2016 |
Malignant Glioma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Enhanced anti-tumor effect of zoledronic acid combined with temozolomide against human malignant glioma cell expressing O6-methylguanine DNA methyltransferase.
|
25111384 |
2014 |
Malignant Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Recently published results of trials on elderly patients with malignant gliomas have revived the call for routine MGMT testing for clinical decision making.
|
23083460 |
2013 |
Malignant Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
To determine the prognostic value of isocitrate dehydrogenase 1 (IDH1) mutation, O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation, and 1p/19q co-deletion in Japanese patients with malignant gliomas.
|
24160898 |
2013 |
Malignant Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
MGMT promoter methylation is a predictive biomarker for benefit from alkylating agent chemotherapy in patients with IDH1-wild-type, but not IDH1-mutant, malignant gliomas of World Health Organization grades III/IV.
|
24068788 |
2013 |
Malignant Glioma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Lack of MGMT protein expression immunohistochemically is related to drug responses in patients with malignant glioma treated with alkylating agents.
|
24374955 |
2013 |
Malignant Glioma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
The O6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation status is a predictive parameter for the response of malignant gliomas to alkylating agents such as temozolomide.
|
22614944 |
2012 |
Malignant Glioma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Resistance of malignant gliomas to TMZ can be overcome by synchronizing metronomic TMZ regimen with MGMT expression.
|
21892781 |
2012 |
Malignant Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Different molecular biomarkers were identified by genetic studies and some of these are used in neuro-oncology for the evaluation of glioma patients, in particular combined deletions of the chromosome arms 1p and 19q in oligodendroglial tumors, methylation status of the O-6 methylguanine- DNA methyltransferase gene promoter and alterations in the epidermal growth factor receptor pathway in adult malignant gliomas, isocitrate dehydrogenase 1 (IDH1) and IDH2 gene mutations in diffuse gliomas, as well as BRAF status in pilocytic astrocytomas.
|
22617234 |
2012 |
Malignant Glioma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
O-methylguanine-DNA methyltransferase (MGMT) mRNA expression predicts outcome in malignant glioma independent of MGMT promoter methylation.
|
21365007 |
2011 |
Malignant Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
According to pathological examination, the tumor was a high-grade glioma that was positive for methylated O-6-methylguanine-DNA methyltransferase promoter.
|
20354758 |
2010 |
Malignant Glioma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
MGMT promoter methylation in malignant gliomas.
|
20725792 |
2010 |
Malignant Glioma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
MGMT promoter methylation in malignant gliomas: ready for personalized medicine?
|
19997073 |
2010 |
Malignant Glioma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
We investigated the impact of MGMT methylation and expression on survival of children with high-grade glioma (HGG) registered into the German HIT-GBM database receiving temozolomide (TMZ) as part of their treatment (n = 21 relapsed, n = 4 primary).
|
19856394 |
2010 |
Malignant Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our findings indicate that, in pHGG, (a) MGMT promoter methylation is less frequent than in adult malignant gliomas, (b) there is a high correlation between MGMT MSP and MGMT IHC, and (c) as in adults, MGMT status is associated with prognosis, although this observation has to be statistically validated on larger series of patients.
|
20552207 |
2010 |
Malignant Glioma
|
0.400 |
Biomarker
|
disease |
CTD_human |
NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.
|
19901110 |
2009 |
Malignant Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
These results suggest that the clinical therapeutic efficacy of TMZ might be improved by a combination with IFN-beta in malignant gliomas unmethylated at the MGMT gene.
|
19513561 |
2009 |
Malignant Glioma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
Aberrant methylation of the MGMT (O6-methylguanine-DNA methyltransferase) DNA-repair gene is a predictive marker for the response to chemotherapy with alkylating agents (e.g., temozolomide) in malignant gliomas.
|
18795231 |
2009 |
Malignant Glioma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
Treatment of recurrent malignant gliomas with fotemustine monotherapy: impact of dose and correlation with MGMT promoter methylation.
|
19335893 |
2009 |
Malignant Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Immediately after the operation, mRNA expression for drug-resistance genes was investigated in frozen samples of malignant gliomas from 55 patients (30 glioblastoma multiformes, 20 anaplastic astrocytomas and 5 anaplastic oligodendroglial tumors) by real-time quantitative RT-PCR with specific primers for MGMT.
|
18575733 |
2008 |